Bioverativ (NASDAQ:BIVV) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Wednesday.

According to Zacks, “Bioverativ Inc. is a biotechnology company. It focuses on the discovery, research, development, and commercialization of innovative therapies for the treatment of hemophilia and other blood disorders. Bioverativ Inc. is based in Waltham, United States. “

A number of other analysts also recently issued reports on BIVV. Morgan Stanley reissued an “underweight” rating and issued a $47.00 target price (up from $45.00) on shares of Bioverativ in a report on Friday, October 6th. Argus raised Bioverativ from a “hold” rating to a “buy” rating and set a $64.00 target price for the company in a report on Wednesday, September 20th. Piper Jaffray Companies reissued an “overweight” rating and issued a $71.00 target price on shares of Bioverativ in a report on Monday, October 23rd. Deutsche Bank set a $53.00 price target on Bioverativ and gave the company a “hold” rating in a research report on Monday, November 20th. Finally, Royal Bank of Canada assumed coverage on Bioverativ in a research report on Thursday, September 14th. They issued a “sector perform” rating and a $59.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $60.33.

Bioverativ (NASDAQ BIVV) traded up $1.03 on Wednesday, reaching $54.95. The company had a trading volume of 851,800 shares, compared to its average volume of 751,650. Bioverativ has a 1 year low of $40.00 and a 1 year high of $64.41. The firm has a market cap of $5,960.00 and a PE ratio of 13.44.

Bioverativ (NASDAQ:BIVV) last announced its quarterly earnings results on Thursday, October 26th. The biotechnology company reported $0.80 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.55 by $0.25. The company had revenue of $291.60 million during the quarter, compared to the consensus estimate of $285.45 million. Bioverativ had a return on equity of 69.03% and a net margin of 40.44%. The firm’s revenue for the quarter was up 27.2% compared to the same quarter last year. research analysts expect that Bioverativ will post 2.45 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently added to or reduced their stakes in BIVV. Advisors Asset Management Inc. purchased a new stake in Bioverativ in the 3rd quarter valued at approximately $137,000. TCI Wealth Advisors Inc. purchased a new stake in Bioverativ in the 3rd quarter valued at approximately $186,000. Ladenburg Thalmann Financial Services Inc. purchased a new stake in Bioverativ in the 3rd quarter valued at approximately $190,000. Canada Pension Plan Investment Board purchased a new stake in Bioverativ in the 3rd quarter valued at approximately $194,000. Finally, ACG Wealth purchased a new stake in Bioverativ in the 3rd quarter valued at approximately $205,000. Institutional investors and hedge funds own 95.99% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece of content was first published by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright laws. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2018/01/03/bioverativ-bivv-cut-to-hold-at-zacks-investment-research.html.

About Bioverativ

Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.

Get a free copy of the Zacks research report on Bioverativ (BIVV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Bioverativ (NASDAQ:BIVV)

Receive News & Ratings for Bioverativ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ and related companies with MarketBeat.com's FREE daily email newsletter.